The votes are in from the FDA's Pharmacy Compounding Advisory Committee (PCAC) July 23-24 meeting, and they went further than almost anyone expected: six of the seven peptides considered were recommended for inclusion on the Section 503A Bulks List — BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon, in both free-base and acetate forms. Only emideltide (DSIP) did not pass, with BMJ reporting that it remained under discussion rather than clearing the bar.
That is the headline. The fine print matters more: the committee overrode FDA's own review staff, which had recommended against all seven substances going into the meeting. The votes are advisory. None of the six can be lawfully compounded today, and the rulemaking that would change that runs through 2027 in the most favorable scenario. A wave of "peptides are legal now" content followed the vote anyway — this piece is the corrective.
What the committee actually voted on
Section 503A of the Food, Drug, and Cosmetic Act permits a state-licensed pharmacy to compound a drug from a bulk substance only if that substance has a USP or NF monograph, is a component of an FDA-approved drug, or appears on the 503A Bulks List codified at 21 CFR 216.23. None of the seven peptides met any of those conditions before this meeting. Getting onto the Bulks List was the entire stakes.
On July 23 the committee took up four substances — BPC-157, KPV, TB-500 and MOTS-c — and recommended all four, as Hyman, Phelps & McNamara's FDA Law Blog reported under the headline of a arriving "peptide wave." On July 24 it took up the remaining three and recommended Semax and Epitalon, while DSIP did not pass. Buchanan Ingersoll's post-meeting analysis counts it plainly: FDA's advisers voted yes on six peptides. The recommendations cover both the free-base and acetate salt forms of each substance, a detail that matters because compounded products are sold in both.
The advisers overrode FDA's own scientists
This is the part of the story consumer coverage keeps losing. As we reported before the meeting, FDA's own briefing materials recommended against adding all seven substances, citing inadequate physicochemical characterization, absent human clinical data for KPV, TB-500 and MOTS-c, immunogenicity concerns, FAERS adverse-event reports for BPC-157, and WADA prohibitions on TB-500 and MOTS-c.
The committee heard that staff review and voted the other way on six of seven. AJMC's August coverage framed it as advisers who "overrode their own scientists" — an accurate description of the mechanics, whatever one thinks of the merits. It is unusual for an advisory committee to reject agency staff recommendations across the board, and it is the strongest signal yet that the political environment around peptide access, which has been warming since the April 2026 Category 2 removals, is reaching the advisory layer.
What the vote does not change
Nothing about the legal status of these six peptides changed on the day of the vote, and nothing changes on the day this publishes. A PCAC recommendation is advice to FDA. The agency must still decide whether to accept it, then run rulemaking: a notice of proposed rulemaking in the Federal Register, a public comment period, and a final rule amending 21 CFR 216.23. Law-firm analyses of the vote put that sequence at 12 to 24 months from acceptance — which puts realistic lawful compounding, if FDA moves at all, in mid-to-late 2027 at the earliest.
Products marketed today as "research peptides" remain outside every one of these pathways. A future favorable rule does not retroactively legalize past sales, and marketing that treats the July vote as a legalization event is describing something that has not happened. Our pre-vote explainer covers the mechanics in depth; the regulatory timeline tracks each milestone as it publishes.
What to watch from here
Four signals, in order. First, FDA's formal meeting minutes and the vote record for each substance, which land on the FDA-2025-N-6895 docket. Second, FDA's response to the recommendations — the agency is not bound and its staff entered the room opposed. Third, a notice of proposed rulemaking for any specific substance, which is the first document that represents actual legal movement. Fourth, the second PCAC meeting covering LL-37, GHK-Cu, dihexa acetate, melanotan II and PEG-MGF, expected before the end of February 2027 — the same process starting over for five more compounds.
The gap between a 6-of-7 advisory vote and a final rule is where most of the misinformation in this niche now lives. Headlines collapse a vote into a law. The distinction is the whole story.